Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Drug

Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial

Fineline Cube May 6, 2025

China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...

Policy / Regulatory

China’s 13 Ministries Release Guidance to Optimize Primary Healthcare Institutions

Fineline Cube May 6, 2025

The National Health Commission, National Development and Reform Commission, and State Commission Office of Public...

Company Drug

AstraZeneca’s Breztri Aerosphere Meets Primary Endpoints in Phase III Asthma Trials

Fineline Cube May 6, 2025

UK-based pharmaceutical firm AstraZeneca (AZ; NASDAQ: AZN) this week unveiled results from the Phase III...

Company

Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound

Fineline Cube May 6, 2025

US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales...

Company Deals

Eucerin Partners with Guangzhou United Family Hospital for Dermatology Services

Fineline Cube May 6, 2025

Eucerin, the dermatology unit of Germany-based skincare firm Beiersdorf AG, has entered into a partnership...

Company Drug

Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial

Fineline Cube May 6, 2025

China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...

Company Drug

Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial

Fineline Cube Apr 30, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted...

Company

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025

Fineline Cube Apr 30, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1...

Company Deals

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China

Fineline Cube Apr 30, 2025

France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...

Company

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands

Fineline Cube Apr 30, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...

Company

Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware

Fineline Cube Apr 30, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...

Company Deals

Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies

Fineline Cube Apr 30, 2025

Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a...

Company Drug

AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis

Fineline Cube Apr 30, 2025

US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...

Company Drug

Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma

Fineline Cube Apr 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...

Company Deals

Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems

Fineline Cube Apr 30, 2025

Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...

Company Deals

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced a strategic partnership...

Company

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025...

Company Medical Device

Roche’s VENTANA TROP2 Device Receives FDA Breakthrough Designation

Fineline Cube Apr 30, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its VENTANA TROP2 (EPR20043) RxDx...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV

Fineline Cube Apr 30, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Company Deals

Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...

Posts pagination

1 … 122 123 124 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.